![]() |
![]() |
Korean J Helicobacter Up Gastrointest Res > Volume 21(2); 2021 > Article |
|
Study | Study period | Treatment | Total GC | SET-like GC | Prevalence of SET-like GC (%) |
---|---|---|---|---|---|
Kawada et al. [2] (1995) | NA | Gastrectomy | 4,920 | 12 | 0.24 |
Takemoto et al. [4] (1995) | 1982~1991 | Gastrectomy | 2,816 | 7 | 0.25 |
Mitsunaga et al. [5] (1995) | 1985~1994 | Gastrectomy | 2,786 | 16 | 0.57 |
Chonan et al. [3] (1995) | 1982~1993 | Gastrectomy | 1,875 | 10 | 0.53 |
Ishiguro et al. [6] (2003) | 1978~2003 | Gastrectomy | 4,743 | 22 | 0.46 |
Yuki et al. [7] (2003) | 1998~2001 | Gastrectomy or endoscopic resection | 866 | 11 | 1.27 |
Study | Sex | Age | Location | Size (cm) | EUS layer | EUS echogenicity | Diagnostic method | Final pathology | AGC/EGC | Classification of mechanism |
---|---|---|---|---|---|---|---|---|---|---|
Ohara et al. [27] (1997) | M | 48 | L | 2.0 | NA | NA | Op | WD adenocarcinoma | AGC | Fibrosis |
Umehara et al. [28] (1999) | M | 50 | U | 3.5 | 3rd, 4th | Hypoechoic | EFB | PD adenocarcinoma | AGC | GCLS |
Hosoda et al. [29] (1999) | M | 71 | Mid | 1.2 | NA | NA | EFB | PD adenocarcinoma | EGC | Others |
Kume et al. [30] (2001) | F | 49 | Mid | 1.0 | 3rd | Hypoechoic | ER | WD adenocarcinoma | EGC | Fibrosis |
Fujiyoshi et al. [31] (2003) | F | 73 | U | 0.7 | 2nd, 3rd | Hypoechoic | EFB | MD adenocarcinoma | EGC | Fibrosis |
Park et al. [8] (2004) | F | 63 | L | 2.3 | NA | NA | Op | Mucinous adenocarcinoma | AGC | Mucinous |
Kim et al. [9] (2005) | F | 63 | L | 1.2 | 3rd | Hypoechoic | ER | Adenocarcinoma | EGC | Others |
Takahashi et al. [32] (2005) | M | 50 | Mid | 2.0 | 3rd | Hypoechoic | Op | GCLS | EGC | GCLS |
Hwang et al. [10] (2006) | F | 44 | Mid | 3.0 | NA | NA | Op | MD adenocarcinoma | EGC | Fibrosis |
Nam et al. [11] (2007) | M | 57 | Mid | 2.5 | 2nd, 3rd | Heterogeneously hypoechoic | EFB | MD adenocarcinoma | EGC | GCLS |
Nam et al. [11] (2007) | F | 46 | Mid | 2.3 | 2nd, 3rd, 4th | Heterogeneously hypoechoic | EFB | SRC | AGC | Others |
Lee et al. [12] (2007) | M | 75 | Mid | 2.0 | 3rd | Hypoechoic | Op | WD adenocarcinoma | EGC | Others |
Hong et al. [13] (2007) | M | 58 | L | 3.0 | NA | NA | Op | GCLS | AGC | GCLS |
Hong et al. [13] (2007) | M | 64 | U | 4.0 | NA | NA | EFB | PD adenocarcinoma | AGC | Others |
Teraishi et al. [33] (2007) | M | 63 | L | 1.3 | 4th | Hypoechoic | EFB | PD adenocarcinoma | AGC | Others |
Eun et al. [14] (2007) | M | 60 | U | 1.0 | 3rd | Hypoechoic | EFB | Adenocarcinoma | EGC | Others |
Ando et al. [34] (2008) | F | 65 | Mid | 1.5 | 3rd | Hypoechoic | Op | Mucinous adenocarcinoma | EGC | Mucinous |
Lee et al. [15] (2009) | M | 43 | U | 2.5 | 3rd | Hypoechoic | Op | PD adenocarcinoma | EGC | GCLS |
Choi et al. [16] (2009) | F | 79 | Mid | 15.0 | 4th | Hypoechoic | EFB | PD adenocarcinoma | AGC | Others |
Kim et al. [17] (2009) | M | 66 | U | 7.3 | 3rd, 4th | Heterogeneously hyperechoic | EFB | Mucinous adenocarcinoma | AGC | Mucinous |
Woo et al. [18] (2010) | M | 34 | U | 1.0 | 3rd | Hypoechoic | ER | GCLS | EGC | GCLS |
Tamura et al. [35] (2010) | M | 83 | Mid | 2.0 | NA | NA | EFB | GCLS | EGC | GCLS |
Kim et al. [19] (2011) | M | 74 | L | 6.0 | 3rd, 4th, 5th | Hypoechoic | EFB | Mucinous adenocarcinoma | AGC | Mucinous |
Gromski et al. [36] (2012) | F | 67 | Mid | 2.0 | 3rd | Hypoechoic | ER | GCLS | EGC | GCLS |
Kim et al. [20] (2012) | M | 57 | Mid | 12.0 | 4th | Heterogeneously mixed echogenic | EUS-TCB | SRC | AGC | Others |
Kim et al. [21] (2013) | F | 63 | L | 1.0 | 2nd, 3rd | Heterogeneously mixed echogenic | ER | MD adenocarcinoma | EGC | GCLS |
Yu et al. [22] (2013) | F | 54 | L | 4.5 | 4th | Heterogeneously mixed echogenic | Op | Mucinous adenocarcinoma | AGC | Mucinous |
Yu et al. [22] (2013) | F | 50 | Mid | 5.0 | NA | NA | Op | Mucinous adenocarcinoma | AGC | Mucinous |
Matsumoto et al. [37] (2013) | M | 58 | U | NA | 3rd | Hypoechoic | EFB | GCLS | EGC | GCLS |
Yoo et al. [23] (2013) | M | 40 | U | 2.5 | 2nd | Heterogeneously hyperechoic | EFB | Mucinous adenocarcinoma | EGC | Mucinous |
Hagiwara et al. [38] (2014) | M | 60 | U | 1.0 | 3rd | Hypoechoic | EFB | WD adenocarcinoma | EGC | Heterotopic gastric gland |
Hagiwara et al. [38] (2014) | M | 60 | U | 3.9 | NA | NA | ER | WD adenocarcinoma | EGC | Heterotopic gastric gland |
Zhang et al. [39] (2014) | M | 64 | U | 1.5 | 3rd | Hypoechoic | Op | GCLS | EGC | GCLS |
Lee et al. [24] (2014) | M | 74 | Mid | 1.5 | 2nd, 3rd | Hypoechoic | ER | GCLS | EGC | GCLS |
Bai et al. [40] (2014) | M | 63 | U | 1.5 | 3rd | Hypoechoic | Op | GCLS | EGC | GCLS |
Imamura et al. [41] (2015) | M | 66 | U | 1.5 | 3rd | Heterogeneously mixed echogenic | LECS | WD adenocarcinoma | EGC | Heterotopic gastric gland |
Li et al. [42] (2016) | M | 44 | U | 1.0 | 4th | Hypoechoic | ER | PD adenocarcinoma | EGC | Others |
Manabe et al. [43] (2017) | M | 58 | U | 1.0 | 3rd | Hypoechoic | ER | Adenocarcinoma | EGC | Heterotopic gastric gland |
Kato et al. [44] (2018) | M | 53 | Mid | 2.0 | 3rd | Hypoechoic | ER | GCLS | EGC | GCLS |
Dong et al. [45] (2018) | M | 41 | L | NA | 3rd, 4th | Hypoechoic | Op | GCLS | AGC | GCLS |
Yang et al. [25] (2019) | F | 78 | U | 6.7 | NA | NA | EUS-FNA | Poorly cohesive carcinoma | AGC | Others |
Cheng and Liu [46] (2019) | M | 50 | L | 1.6 | 3rd | Hypoechoic | ER | PD adenocarcinoma | EGC | Others |
Namikawa et al. [47] (2019) | M | 85 | Mid | 2.8 | NA | NA | EFB | WD adenocarcinoma | EGC | Heterotopic gastric gland |
Yamane et al. [48] (2019) | M | 81 | Mid | 3.0 | 3rd | Hypoechoic | EUS-FNA | PD adenocarcinoma | AGC | Others |
Chen et al. [49] (2019) | F | 48 | U | 2.0 | NA | NA | Op | MD adenocarcinoma | AGC | Others |
Uozumi et al. [50] (2019) | M | 73 | U | 2.5 | 3rd | Hypoechoic | ER | Adenocarcinoma | EGC | Heterotopic gastric gland |
Tanabe et al. [51] (2019) | F | 76 | Mid | 2.0 | 3rd, 4th | Hypoechoic | EUS-FNA | GCLS | AGC | GCLS |
Kobayashi et al. [52] (2019) | F | 72 | Mid | 2.0 | 3rd | Hypoechoic | ER | PD adenocarcinoma | EGC | GCLS |
Kobayashi et al. [52] (2019) | M | 73 | Mid | 1.5 | 3rd | Hypoechoic | ER | GCLS | EGC | GCLS |
Lee et al. [26] (2020) | F | 64 | Mid | 2.0 | 4th | Heterogeneously hypoechoic | Op | SRC | AGC | Others |
Ozawa et al. [53] (2020) | M | 80 | Mid | 2.0 | 2nd, 3rd | Hypoechoic | LECS | MD adenocarcinoma | AGC | Others |
Wada et al. [54] (2020) | M | 65 | U | 1.0 | 3rd | Hypoechoic | EFB | Papillary adenocarcinoma | AGC | Heterotopic gastric gland |
Yanagita et al. [55] (2021) | M | 78 | Mid | 2.0 | 3rd | Hypoechoic | EUS-FNA | GCLS | EGC | GCLS |
EUS, endoscopic ultrasound; AGC, advanced gastric cancer; EGC, early gastric cancer; M, male; L, lower third (antrum, angle); NA, not available; Op, operation; WD, well differentiated; U, upper third (high body, fundus, cardia); EFB, endoscopic forcep biopsy; PD, poorly differentiated; GCLS, gastric carcinoma with lymphoid stroma; Mid, middle third (low to mid body); F, female; ER, endoscopic resection; MD, moderately differentiated; SRC, signet-ring cell carcinoma; EUS-TCB, endoscopic ultrasound-guided trucut biopsy; LECS, laparoscopic and endoscopic cooperative surgery; EUS-FNA, endoscopic ultrasound-guided fine-needle aspiration.
Histopathology of Gastric Cancer2023 June;23(2)
Subepithelial Tumor Diagnosed after Endoscopic Submucosal Dissection2022 December;22(4)
Diffuse-type Gastric Cancer2022 March;22(1)
Common Gastric Subepithelial Tumors in Koreans2022 March;22(1)
Proton Pump Inhibitors and Gastric Cancer2021 September;21(3)
![]() |
![]() |